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Hormonal therapy is the preferred systemic treatment for recurrent or metastatic, post-menopausal hormone-receptor-positive
breast cancer. Previous studies have shown that there is no cross-resistance between exemestane and reversible aromatase
inhibitors. Exposure to hormonal therapy does not hamper later response to chemotherapy. Patients with locally advanced or
metastatic, hormonal receptor positive or unknown, breast cancer were treated with oral anastrozole, until disease progression,
followed by oral exemestane until new evidence of disease progression. The primary end point of the study was clinical benefit,
defined as the sum of complete responses (CR), partial responses (PR) and 424 weeks stable disease (SD). In all, 100 patients were
enrolled in the study. Anastrozole produced eight CR and 19 PR for an overall response rate of 27% (95% CI: 18.6–36.8%). An
additional 46 patients had long-term (424 weeks) SD for an overall clinical benefit of 73% (95% CI: 63.2–81.4). Median time to
progression (TTP) was 11 months (95% CI: 10–12). A total of 50 patients were evaluated for the second-line treatment: exemestane
produced one CR and three PR; 25 patients had SD which lasted X6 months in 18 patients. Median TTP was 5 months. Toxicity of
treatment was low. Our study confirms that treatment with sequential hormonal agents can extend the period of time during which
endocrine therapy can be used, thereby deferring the decision to use chemotherapy.
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Treatment of metastatic breast carcinoma is still controversial. The
introduction of new cytotoxic drugs and new chemotherapic
regimens has, up to now, not resulted in a significant increase in
survival.
Endocrine therapy is the preferred systemic treatment for
recurrent or metastatic hormone-receptor-positive post-meno-
pausal breast cancer (Carlson and Henderson, 2003), since it is well
known that breast cancers expressing the oestrogen receptor (ER)
and/or progesterone receptor (PgR) are sensitive to an increasingly
wide variety of hormonal therapies (Carlson, 2002). Many patients
who have been treated with Tamoxifen (Tam), which is still the
standard hormonal treatment for breast carcinoma in the adjuvant
setting, need new drugs with antiproliferative effects on oestro-
gen-dependent breast tumours. The available therapies include
Tamoxifen or ovarian ablation (surgical oophorectomy, radiothera-
peutic ablation or pharmacologically induced) in pre-menopausal
women, Tamoxifen or aromatase inhibitors (AIs) in post-meno-
pausal women, and the progestins, androgens and high-dose
oestrogens for both pre- and post-menopausal patients.
Importantly, exposure to endocrine treatment does not
seem to hamper later response to chemotherapy (Taylor et al,
1986). Since the goal of treating metastatic breast cancer is
palliative (Hortobagyi, 1998a), minimally toxic alternatives are
needed to improve clinical symptoms, to maintain acceptable
performance status and quality of life, and to delay the need for
chemotherapy. As endocrine therapies have developed, it has
become recognised that a response to one therapy is predictive of
a response to further hormonal therapy (Buzdar and Hortobagyi,
1998; Hortobagyi, 1998b). The sequential use of endocrine
therapy alone offers significant quality-of-life advantages over
cytotoxic chemotherapy (Buzdar and Hortobagyi, 1998), since it
offers disease control without the side effects associated with
cytotoxic agents. The development of novel endocrine therapies
may extend the period of time during which sequential endo-
crine therapy can be used, thereby postponing the need for
cytotoxic chemotherapy. Traditionally, the sequence of endocrine
therapies was determined by the relative toxicity of the respective
agents, with the least toxic being used first. However, more
recently, the relative efficacy of agents has become an increa-
singly important consideration, particularly since AIs have been
shown to represent clinically relevant alternatives to Tamoxifen in
women with hormone receptor-positive breast cancer (Carlson
et al, 2003).
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sAnastrozole (AN), the first third-generation nonsteroidal AI
approved in the USA, acts by reversibly binding to the aromatase
enzyme and shows a low toxic profile, because it does not inhibit
the production of adrenal steroids, nor does it determine the
occurrence of thrombotic events as frequently as with tamoxifen
(Bonneterre et al, 1999). The rationale for the use of this drug as
first-line therapy in postmenopausal patients is supported by
European (Robertson et al, 1999) and American (Nabholtz et al,
2000) phase III studies vs tamoxifen, which have demonstrated an
equivalent efficacy, an increase in time to progression (TTP; 11.1
months for AN and 5.6 months for Tam) and a lower incidence
of thrombotic events, indicating the possibility of considering AN
as a first-line treatment for patients with advanced breast
carcinoma. On the other hand, negative data have also been
reported (Nabholtz et al, 2003).
Exemestane (Exe) is a second-generation, steroidal AI which
irreversibly binds to the enzyme aromatase. The novel aromatase
inactivator Exe has been evaluated extensively in phase I and II
studies at dosages of up to 600mgday
 1. It is well tolerated and, as
a consequence, a maximum-tolerated dose has not been identified
(Di Salle et al, 1994; Johannessen et al, 1997). Oral Exe 10–
25mgday
 1 suppresses plasma oestrogens to as much as 6–15%
of pretreatment levels (Johannessen et al, 1997). In two phase II
uncontrolled studies, objective response (OR) rates with Exe as
second-line therapy in postmenopausal women with advanced
breast cancer were 22 and 28%, and overall success rates (defined
as the proportion of patients with OR or stable disease (SD) for
X24 weeks; sometimes described by other authors as ‘clinical
benefit’ (Buzdar et al, 1998; Dombernowsky et al, 1998) were 47
and 48%, respectively (Jones et al, 1998; Kvinnsland et al, 1998).
Phase II studies suggest that there is no cross-resistance between
Exe and reversible inhibitors of aromatase and that the tolerability
profile is excellent. Therefore, a sequential approach with AN
followed by exemestane is worth pursuing, even upon the
availability of newer compounds such as fulvestrant and trilostane.
On the basis of these considerations, we performed a phase II
study which evaluated the activity of AN, a type II AI, as a first-line
drug, and, in the event of disease progression, of exemestane, type
I, in patients with metastatic breast carcinoma.
MATERIALS AND METHODS
Patient selection
This study was initiated in November 2000 and closed to accrual in
November 2002, was conducted at 13 sites within the Gruppo
Oncologico Italia Meridionale (GOIM – Southern Italy Oncology
Group). All patients were required to have a cytological or
histological confirmed diagnosis of locally advanced or metastatic
or primary breast cancer, not susceptible to surgical or radiological
treatment and measurable disease.
All patients were required to have an ECOG performance status
(WHO scale) p2, and to be postmenopausal or premenopausal
in treatment with LH–RH agonist. Postmenopausal women were
defined as those X50 years of age who had not menstruated during
the preceding 12 months or who had castrate follicle-stimulating
hormone levels (440IUl
 1), those younger than 50 years of age
who had castrate follicle-stimulating hormone levels (440IUl
 1)
or those who had undergone a bilateral oophorectomy.
Prior adjuvant chemotherapy or hormonal therapy with
Tamoxifen for early breast cancer was permitted, provided that
the patient had not received tamoxifen in the 6 months prior to
entry into the trial.
Patients were required to have tumours that were ER-positive
and/or PgR-positive or were of unknown receptor status. Patients
with negative receptors or with one negative and the other
unknown were excluded from the study. Other exclusion criteria
were patients with cerebral metastasis, diffuse bilateral lymphan-
gitis or patients with only osteoblastic bone metastasis, or with
both lytic and osteoblastic lesions in which fewer than 50% of the
lesions were lytic, when there were not other measurable lesions.
Patients with more than one previous chemotherapeutic line for
metastatic disease, prior therapy with AIs, uncontrolled cardio-
logic dysfunctions, a low compliance to treatment, and other
concomitant or previous malignancies (except for basal cell
carcinoma and carcinoma in situ of the cervix) were excluded,
too. The study was approved by the Ethic Committees of the
participating centres and all patients gave their informed written
consent.
Treatment plan
Eligible patients were treated as follows: AN, one 1mg tablet daily,
until clear evidence of progression; exemestane, one 25mg tablet
daily, from evidence of progression after AN therapy until further
evidence of disease progression. Subsequent therapy was left up
to the discretion of the investigator, and follow-up was performed
until death.
Patient evaluations
Baseline screening assessments were completed 2 weeks before the
treatment. These assessments included demographic information,
a complete history and a clinical visit to document the sites of
disease. Laboratory studies included chest X-ray, liver scan by
ultrasound, computed tomography (CT) scan, or magnetic
resonance imaging, bone scan, and bone survey or X-rays of areas
that were found suggestive of abnormality on the bone scan. Blood
samples were collected for haematology and blood chemistry
(general and specific, tumour markers). A history of disease-
related symptoms was also documented.
A clinical visit, general and specific (tumour markers)
laboratory procedures, total-body CT scan were repeated at a
3-months interval; bone scans were repeated every 12 months.
Response to treatment was evaluated according to RECIST
criteria. Time to progression was measured in all patients as the
time (in months) from the start of study drug to the date of
evidence of progressive disease or death (or last follow-up in
absence of unfavourable event). Toxicity was evaluated according
to CTC criteria (CTC version 2.0. Cancer Therapy Evaluation
Program. Common Toxicity Criteria, Version 2.0. DCTD, NCI,
NIH, DHHS. March 1998. Publish Date: April 1999).
Patients were withdrawn from active treatment if there was
evidence of clinically significant breast cancer progression, or a
serious adverse event. Patient noncompliance with protocol
procedures, or unwillingness or inability to continue the trial
was also a reason for patient removal from the trial.
Statistical considerations
The primary objective of the study was to evaluate the study drugs
in terms of clinical benefit (complete response (CR)þpartial
response (PR)þstabilisation of disease (SD) 46 months).
Secondary objectives were major (CRþPR) response rate, TTP
and toxicity. The sample size calculation for both single-stage
studies was performed as proposed by A’Hern (2001), this method
being an exact version of the algorithm first presented by Felming
(1982).
The AN evaluation required 93 subjects to decide whether the
proportion of patients with a clinical benefit (P) was p50% or
X65%. If the number of patients with clinical benefit was X55, the
hypothesis that Pp50% was rejected with a target error rate of
0.050 and an actual error rate of 0.048. If the number of patients
with clinical benefit was p54, the hypothesis that PX65% was
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srejected with a target error rate of 0.100 and an actual error rate of
0.099.
The exemestane evaluation required 47 subjects to decide
whether P was p20% or X40%. If the number of patients with
clinical benefit was X15, the hypothesis that Pp20% was rejected
with a target error rate of 0.050 and an actual error rate of 0.037.
If the number of patients with clinical benefit was p14, the
hypothesis that PX40% was rejected with a target error rate of
0.100 and an actual error rate of 0.099.
RESULTS
Patient population
Between November 2000 and November 2002, 100 patients aged
30–93 years (median: 66) were enrolled in the study. The patient
characteristics are presented in Table 1.
First-line AN
Eight CRs (8%) and 19 PRs (19%) were observed, providing an OR
rate of 27% (95% CI: 18.6–36.8%). In all, 46 additional patients
had a long-term disease stabilisation (SD after X6 months),
providing a clinical benefit rate of 73% (95% CI: 63.2–81.4); thus,
AN was considered as active at the level of clinical interest as above
defined. Five other patients had a stabilisation lasting 4–6 months,
and 19 had a PD (see Table 2). Three patients were not evaluable
for response: one had a severe osteo-arthromyalgia, and two left
the study by their own choice (in the absence of PD or any evident
adverse reaction).
In all, 84 patients discontinued the first-line AN therapy, three
before evaluation of activity (see above) and 81 because of a PD.
The median duration of AN therapy was 9 months (range: 3–30þ
months), for a median follow-up of 15 months (range: 3–32þ
months). The median Kaplan–Meier progression-free survival
estimate was 11 (95% CI: 10–12) months (Figure 1).
First-line AN was well tolerated. No patient manifested any
thrombo-embolic event or bone fracture. Seven (7%) patients had
a grade 1–2 osteo-articular pain, 20 (20%) manifested hot flushes
and 19 (19%) manifested a grade 1–2 nausea and vomiting.
Second-line exemestane
Five of 13 treatment centres did not agree to participate in the
activity trial of exemestane in patients progressing after first-line
AN; thus, 50 patients were eligible for this study. One CR (2%) and
three PR (6%) were observed in patients treated with exemestane,
for an overall response rate of 8% (95% CI: 2.2–19.2%) (see
Table 2). The patient who achieved a CR had had a CR also
following first-line AN therapy; on the other hand, all of the three
patients who achieved a PR following exemestane had progressed
while on previous AN therapy.










Hormonal only 21 21




Sites of metastatic disease
Bone 52 52 30 60
Skin 11 11 6 12
Lymph 16 16 9 18
Pleural effusion 6 6 5 10
Liver 19 19 15 30
Lung 14 14 10 20
Breast 17 17 10 20
Numbers of sites involved
16 4 6 4 2 3 4 6
22 6 2 6 1 5 3 0
38 8 1 0 2 0
442 2 2 4
Performance Status
04 3 4 3 2 1 4 2
14 0 4 0 1 9 3 8
21 7 1 7 1 0 2 0
Receptor status
ER+, PgR+ 66 67
ER+, PgR  88
ER+, PgR unknown 0 0
ER , PgR+ 5 5
ER unknown, PgR+ 0 0
Unknown 19 19





Response n¼100 (%) n¼50 (%)
CR 8 (8%) 1 (2%)
PR 19 (19%) 3 (6%)
Objective response rate 27 (27%) 4 (8%)
SDX24 weeks 46 (46%) 18 (36%)
Clinical benefit (CR+PR+SDX24
weeks)
73 (73%) 22 (44%)
SDo24 weeks 5 (5%) 7 (14%)
Progression 19 (19%) 20 (40%)
Figure 1 Progression-free survival.
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sIn all, 18 additional patients had a long-term disease stabilisa-
tion (X6 months), providing a clinical benefit rate of 44% (95%
CI: 30.0–58.7%); seven other patients had a stabilisation lasting
4–6 months. Among the 25 patients who had SD following
exemestane therapy, 24 had previously responded to AN; however,
the only patient with SD who had previously had a PD following
AN had the longest SD duration (25þ months).
Altogether, 20 patients had a PD at exemestane evaluation, and
one patient was not evaluable for response because of a treatment-
limiting gastro-intestinal pain.
In all, 46 patients discontinued the second-line, exemestane
therapy; 45 because of a PD, and one because of gastro-intestinal
pain. The median duration of exemestane therapy and follow-up
was 5 months (range: 3–25þ months). The median Kaplan–
Meier, progression-free survival estimate was 5 (95% CI: 3–7)
months (Figure 1).
Also, second-line exemestane was well tolerated. No patient
manifested any thrombo-embolic event or bone fracture. Five
(10%) patients had a grade 1–2 osteo-articular pain, 10 (20%)
manifested hot flushes and 12 (24%) manifested a grade 1–2
nausea and vomiting. Moderate grade fatigue was reported in 14%
of patients.
DISCUSSION
Over the last few years, with the widespread availability of
letrozole, AN and exemestane, the goal of developing highly
effective, well-tolerated, orally active AIs has been realised.
Data from two recent trials that compared AN with megestrol
Acetate in second line confirmed that AN was well tolerated,
produced response rates similar to megestrol and determined a
significant improvement in global survival although it was not
associated with the increase in weight produced by megestrol
acetate (Buzdar et al, 1996).
Two similar studies with letrozole in patients in relapse with
adjuvant tamoxifen or first-line antioestrogens, demonstrated that
letrozole can obtain efficiency results similar or superior to
megestrol acetate (Dombernowsky et al, 1998; Buzdar et al, 2001).
Exemestane, the most recently introduced AI, obtained a
significant improvement in survival compared to megestrol acetate
(Kaufmann et al, 2000).
Both AN and letrozole seem to offer greater effectiveness than
tamoxifen in the first-line treatment of women in menopause
and with positive receptors (Bonneterre et al, 2001; Mouridsen
et al, 2001).
Now there is clear evidence in the international scientific
community that these third-generation AIs represent credible
therapeutic options such that they can be used in first line at the
first relapse in post-menopausal women whether or not they have
received adjuvant treatment with tamoxifen. The issue of
sequential hormonal treatment has been addressed in clinical
studies in which AN was given either before tamoxifen or upon
progression on tamoxifen (Thu ¨rlimann et al, 2000, 2002).
Encouraging overall response rates and meaningful clinical benefit
were observed in all of these studies.
Exemestane showed activity in patients in progression after
prior treatment with nonsteroidal AIs. Good results were observed
in terms of OR and clinical benefit in a comprehensive percentage
of over 30% (Lønning et al, 2000). In so much as these data are less
favourable than those reported with tamoxifen after AN, it is, in
any case, confirmed that there is an interest in using exemestane in
third line for patients pretreated both with tamoxifen and with
non-steroidal AIs.
The rationale for the sequential use of triazole derivatives, such
as AN, and steroidal compounds, such as exemestane, lies in the
difference between the two classes of compounds with respect to
their biochemical action on the aromatase enzyme. In fact, while
nonsteroidal compounds bind to the p450 site of the aromatase
complex, the steroidal compounds bind to the substrate-binding
pocket.
The results of our work show several interesting aspects. First of
all, the toxicity level was especially low; treatment was suspended
in only two cases, once in first-line therapy and once in second
line, and there were no noteworthy signs of thromboembolism.
This allowed sequential treatment to be carried out even for long
periods of time with a good quality of life and absolute normalcy of
vital functions in almost all patients. If the total of ORs (CRþPR)
is consistent with that described in international literature for first-
line treatments, the duration of response and TTP was consider-
able. Clinical benefit was even more important because of the high
percentage of long-lasting SD. This very encouraging result can
probably be explained by the high percentage of patients with a
known receptorial state and the low percentage of visceral
metastases.
Results of second-line responses showed clear evidence of an
absence of cross-resistance between the two treatments, which is
the consequence of the different mechanism of action. The
observed high TTP in second line is also to be noted. There is
no doubt that, overall, the data of our study confirm the usefulness
of sequential hormonal treatment for patients with adequate
clinical indication. A brief reflection should be made on the drop-
out of about 50% of the patients in second-line treatment. This is
frequently due to a widely shared opinion that chemotherapy
could be a better therapeutic option in this setting. This view is
very common especially among patients and relatives, and does of
course influence medical behaviour.
In conclusion, our study gives clear insights into the feasibility
and activity of a sequential hormonal approach in the treatment
of selected patients with advanced breast cancer. Future studies
with this sequential combination of AN and exemestane will help
to clarify the real allocation in the therapeutic armamentarium
against advanced breast cancer. Along with the use of new
upcoming hormonal agents, this may represent a valuable
approach which can, at least, defer the start of chemotherapy.
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